Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation

    Journal Title:  Blood Cancer J Primary Author:  Sugimori C Author(s):  Sugimo...

    Research Article last updated 07/31/2012 - 12:36pm.

  2. From Patient to PhD Candidate

    ... gene is often mutated in AML patient genomes, and this mutation is responsible for malignant reduction of blood lineages. Thus, ...

    Patient Chronicle last updated 06/12/2017 - 2:59pm.

  3. David Araten, MD

    ... cells. This clone has as its feature the presence of a mutation in a gene called PIG-A. Different patients have different types of ... PNH. We have recently found 4 patients with PNH who have a mutation in genes other than PIG-A--  the JAK2 and the TET2 genes. Three out ...

    Grant Recipient last updated 11/30/2016 - 10:51am.

  4. Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation

    ... advanced hematologic malignancies that harbor an IDH2 mutation . The study includes a dose escalation phase to determine the ...

    Clinical Trial last updated 05/03/2016 - 11:40am.

  5. Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

    ... in advanced hematologic malignancies that harbor an IDH1 mutation . The first portion of the study is a dose escalation phase where ...

    Clinical Trial last updated 05/03/2016 - 11:37am.

  6. Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis

    ... to calculate the prognostic significance of SETBP1 mutation in patients. RESULTS: A total of 12 studies with 2321 ... CONCLUSIONS: Current evidence shows that SETBP1 mutation is associated with a poor prognosis in patients with MDS and CMML, but ...

    Research Article last updated 02/21/2017 - 10:33am.

  7. Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights

    ... About 90% of patients harbor at least one somatic mutation . This review aimed to assess the potential of molecular ... In addition, patients with del5q subtype harboring TP53 mutation do not show a good response to lenalidomide therapy. In ...

    Research Article last updated 02/01/2017 - 8:15am.

  8. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

    ... at multiple time points to evaluate patterns of mutation clearance in 54 patients. An extension cohort included 32 ... had favorable clinical responses and robust (but incomplete) mutation clearance after receiving serial 10-day courses of decitabine. ...

    Research Article last updated 01/26/2017 - 10:07am.

  9. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications

    ... the size of the TP53 mutant clone as measured by mutation allele burden is directly linked to overall survival (OS) ...

    Research Article last updated 01/26/2017 - 10:06am.

  10. Pathogenesis of paroxysmal nocturnal hemoglobinuria

    ... (PNH) is an acquired GPI deficiency caused by somatic mutation of the PIGA gene in one or several hematopoietic stem cells . Recently, PNH caused by somatic mutation of one allele of the PIGT gene in combination with a germline mutation ...

    Research Article last updated 11/02/2016 - 2:52pm.